About RanD
RanD is a company based in Medolla (Italy) founded in 1999 was acquired by Continental Investment Partners in October 2024. RanD offers products and services including Performer 3, Performer HT, and Perfusion Service. RanD operates in a competitive market with competitors including ChemoTech, Nativis, IGEA and Papyrus Therapeutics, among others.
- Headquarter Medolla, Italy
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Rand S.P.A.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
- Investors
-
Employee Count
Not available
-
Acquired by
Continental Investment Partners
(Oct 15, 2024)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of RanD
RanD offers a comprehensive portfolio of products and services, including Performer 3, Performer HT, and Perfusion Service.
Advanced medical system for hyperthermic perfusion in oncology treatments.
System designed for hyperthermic intraperitoneal chemotherapy procedures.
Provides support for extracorporeal circulation in surgical applications.
Funding Insights of RanD
Detailed funding history for RanD
Round names, dates, amounts, investors, and valuation history require an active premium plan.
- Round names and dates
- Funding amounts
- Participating investors
- Valuation history
Verified entity values are shown only after access is granted.
Investors in RanD
RanD has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Continental Investment Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investments in companies and real estate operations are facilitated.
|
Locked | Locked | Locked |
Investor details for RanD
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by RanD
Investment portfolio details for RanD
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - RanD
Detailed financials for RanD
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Rand Comparisons
Peer comparison for RanD
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of RanD
RanD operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as ChemoTech, Nativis, IGEA and Papyrus Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of electroporation devices for the treatment of cancer
|
|
| Locked | Locked | Locked |
Developer of a therapeutic device for the treatment of cancer
|
|
| Locked | Locked | Locked |
Orthopedic medical devices to promote reparative osteogenesis and joint protection
|
|
| Locked | Locked | Locked |
Develops therapies for tumor suppression in various cancers through scientific research.
|
Detailed competitors of RanD
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Rand
Complete news archive for RanD
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about RanD
RanD was founded in 1999.
RanD is headquartered in Medolla, Italy. It is registered at Medolla, Emilia-romagna, Italy.
RanD was established in 1999 in Medolla, Italy, within the medical devices sector. Focus is placed on surgical oncology through the creation of innovative systems utilizing extracorporeal circulation technologies. Operations encompass the provision of products for liver support, cardiopulmonary support, and dialysis. Activities are centered on advancing these technologies for clinical applications in oncology and related fields.
RanD offers Performer 3, Performer HT, and Perfusion Service.
RanD has 1 investor. Key investors include Continental Investment Partners.